Clinical Trial · NCT01801371

68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma

Overview

This is an open-label brain PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in glioma patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤40 µg BNOTA-PRGD2) will be intravenously injected into patients in suspicion of glioma. Visual and semiquantitative method will be used to assess the PET/CT images. Brain MRI with/without enhancement and 18F-FDG PET/CT will be performed for comparison. The postoperative pathology and integrin αvβ3 and CD34 immunohistochemical stains will also be used for correlation.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu, MD (CONTACT)

zzh_1969@yahoo.com.cn

86-10-69154196

Zhaohui Zhu, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01801371

Drug / Compound

BNOTA-PRGD2

Isotope(s):

Target(s):

αvβ3

Ligand Class: Peptides

Chelator: NOTA

Linker: PEG3

Eligibility

Inclusion

In suspicion of brain glioma on MRI；
The tumor will be surgically removed and histological diagnosis will be available.

Exclusion

Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.